PDF(Pubmed)
Abstract：
Aromatase inhibitors (AIs) have shown great success as adjuvant therapy for post-menopausal women with hormone receptor-positive breast cancers. AI-induced arthralgia (AIA) is a frequent AI toxicity contributing to non-adherence and discontinuation. This review aims to understand current knowledge of AIA. The mean incidence of AIA was 39.1% and the mean discontinuation of AI therapy due to AIA was 9.3%. Most of the AIAs were non-inflammatory. A shorter time since the last menstrual period and pre-existing joint pain were risk factors. Vitamin D3 supplementation may be a preventative measure and treatment with duloxetine, acupuncture and/or exercise is supported by large randomized controlled trials. There was consistent improvement in AIAs with switching to an alternate AI, and this could additionally allow continuation of cancer treatment with AI. Further research is needed to identify predictive biomarkers, better characterize AIA subcategories and study more reliable therapeutic options.
摘要：
芳香化酶抑制剂（AIs）作为激素受体阳性乳腺癌绝经后妇女的辅助治疗已显示出巨大的成功。AI诱发的关节痛（AIA）是一种常见的AI毒性，可导致不坚持和停药。这篇综述旨在了解AIA的最新知识。AIA的平均发生率为39.1％，因AIA而停止AI治疗的平均发生率为9.3％。大多数AIA是非炎性的。自上次月经期以来的较短时间和预先存在的关节痛是危险因素。补充维生素D3可能是度洛西汀的预防措施和治疗方法，针灸和/或运动得到大型随机对照试验的支持.随着切换到替代AI，AIA得到了持续的改善，这还可以继续使用AI进行癌症治疗。需要进一步的研究来确定预测性生物标志物，更好地表征AIA子类别，并研究更可靠的治疗选择。
